Alzheimer's Disease

References

Allison, A.C. The possible role of vitamin K deficiency in the pathogenesis of Alzheimer's disease and in augmenting brain damage associated with cardiovascular disease. Med. Hypotheses 2001; 57(2): 151-5.

Anon. Idebenone (monograph). Altern. Med. Rev. 2001; 6(1): 83-6.

Anthony, J.C., Breitner, J.C. et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County Study. Neurology 2000; 54(11): 2066-71.

Arai, H., Suzuki, T. et al. A new interventional strategy for Alzheimer's disease by Japanese herbal medicine. Nippon Ronen Igakkai Zasshi 2000; 37(3): 212-5.

Bai, D.L., Tang, X.C. et al. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr. Med. Chem. 2000; 7(3): 355-74.

Barak, Y., Levine, J. et al. Inositol treatment of Alzheimer's disease: a double blind, cross-over placebo controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 1996; 20(4): 729-35.

Bastianetto, S., Ramassamy, C. et al. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur. J. Neurosci. 2000; 12(6): 1882-90.

Beal, M.F. Mitochondria, NO and neurodegeneration. Biochem. Soc. Symp. 1999; 66: 43-54.

Behl, C. Vitamin E protects neurons against oxidative cell death in vitro more effectively than 17-beta estradiol and induces the activity of the transcription factor NF-kappaB. J. Neural Transm. 2000; 107(4): 393-407.

Bergamasco, B., Scarzella, L. et al. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct. Neurol. 1994; 9(3): 161-8.

Bertoni-Freddari, C., Giuli, C. et al. The effect of chronic hydergine treatment on the plasticity of synaptic junctions in the dentate gyrus of aged rats. J. Gerontol. 1987; 42(5): 482-6.

Birks, J., Evans, J.G. et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev. 2000a; 4.

Birks, J.S., Melzer, D. et al. Donepezil for mild and moderate Alzheimer's disease. Cochrane Database Syst. Rev. 2000b; 4.

Blusztajn, J.K., Liscovitch, M. et al. Phosphatidylcholine as a precursor of choline for acetylcholine synthesis. J. Neural Transm. Suppl. 2000; 24: 247-59.

Booth, A.A., Khalifah, R.G. et al. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J. Biol. Chem. 1997; 272(9): 5430-7.

Booth, A.A., Khalifah, R.G. et al. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem. Biophys. Res. Commun. 1996; 220(1): 113-9.

Bopp-Kistler, I., Ruegger-Frey, B. et al. Vitamin B12 deficiency in geriatrics. Schweiz. Rundsch. Med. Prax. 1999; 88(45): 1867-75.

Bottiglieri, T., Hyland, K. S-Adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurol. Scand. Suppl. 1994; 154: 19-26.

Brusco, L.I., Fainstein, I. et al. Effect of melatonin in selected populations of sleep-disturbed patients. Biol. Signals Recept. 1999; 8(1-2): 126-31.

Brusco, L.I., Marquez, M. et al. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol. Lett. 2000; 21(1): 39-42.

Butterworth, R.F. Evidence for forebrain cholinergic neuronal loss in congenital ornithine transcarbamylase deficiency. Metab. Brain Dis. 2000; 15(1): 83-91.

Carlson, L.E., Sherwin, B.B. et al. Relationships between dehydroepiandrosterone sulfate (DHEAS) and cortisol (CRT) plasma levels and everyday memory in Alzheimer's disease patients compared to healthy controls. Horm. Behav. 1999; 35(3): 254-63.

Chapman, P.F. Alzheimer's disease: model behaviour. Nature 2000; 408(6815): 915-6.

Cheng, D.H., Ren, H. et al. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 1996; 8(1): 97-101.

Christen, Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 2000; 71(2): 621S-629S.

Clarke, R., Smith, A.D. et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol. 1998; 55(11): 1449-55.

Corrigan, F.M., Van Rhijn, A. et al. Essential fatty acids in Alzheimer's disease. Ann. N.Y. Acad. Sci. 1991; 640: 250-2.

Crapper McLachlan, D.R., Dalton, A.J. et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991 Jun 1; 337(8753): 1304-8.

Crook, T., Petrie, W. et al. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol. Bull. 1992; 28(1): 61-6.

Cummings, J.L. Treatment of Alzheimer's disease. Clin. Cornerstone 2001; 3(4): 27-39.

Delwaide, P.J., Gyselynck-Mambourg, A.M. et al. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol. Scand. 1986; 73(2): 136-40.

Diamond, B.J., Shiflett, S.C. et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch. Phys. Med. Rehab. 2000; 81(5): 668-78.

Doody, R.S. Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology 1999a; 45(Suppl. 1): 23-32.

Doody, R.S. Therapeutic standards in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1999b; 13(Suppl. 2): S20-S26.

Dringenberg, H.C., Laporte, P.P. et al. Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence. Neuroreport 2000; 11(16): 3513-6.

Eastley, R., Wilcock, G.K. et al. Vitamin B12 deficiency in dementia and cognitive impairment: the effects of treatment on neuropsychological function. Int. J. Geriatr. Psychiatry 2000; 15(3): 226-33.

Eckert, G.P., Cairns, N.J. et al. Piracetam reverses hippocampal membrane alterations in Alzheimer's disease. J. Neural Transm. 1999; 106(7-8): 757-61.

Engel, R.R., Satzger, W. et al. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur. Neuropsychopharmacol. 1992; 2(2): 149-55.

Filip, V., Kolibas, E. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J. Psychiatry Neurosci. 1999; 24(3): 234-43.

Fitten, L.J., Perryman, K.M. et al. Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. Am. J. Psychiatry 1990; 147(2): 239-42.

Foster, R.H., Plosker, G.L. Donepezil. Pharmacoeconomic implications of therapy. Pharmacoeconomics 1999; 16(1): 99-114.

Gelowitz, D.L., Paterson, I.A. Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration. Pharmacol. Biochem. Behav. 1999; 62(2): 255-62.

Giem, P., Beeson, W.L. et al. The incidence of dementia and intake of animal products: preliminary findings from the Adventist Health Study. Neuroepidemiology 1993; 12(1): 28-36.

Goldsmith, H.S. Abdominal omentum transfer and the nervous system. Lancet 1985; 1(8444): 1514.

Goldsmith, H.S., Chen, W.F. et al. Brain vascularization by intact omentum. Arch. Surg. 1973; 106(5): 695-8.

Goldsmith, H.S., Griffith, A.L. et al. Lipid angiogenic factor from omentum. JAMA 1984a; 252(15): 2034-6.

Goldsmith, H.S., Steward, E. Vascularization of brain and spinal cord by intact omentum. Appl. Neurophysiol. 1984b; 47(1-2): 57-61.

Goldsmith, H.S., McIntosh, T. et al. Vasoactive neurochemicals identified in omentum: a preliminary report. Br. J. Neurosurg. 1987; 1(3): 359-64.

Gottfries, C.G., Lehmann, W. et al. Early diagnosis of cognitive impairment in the elderly with the focus on Alzheimer's disease. J. Neural Transm. 1998; 105(8-9): 773-86.

Grilli, M.M.M. Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction. Biochem. Pharmacol. 1999; 57(1): 1-7.

Grobe-Einsler, R. Clinical aspects of nimodipine. Clin. Neuropharmacol. 1993; 16(Suppl. 1): S39-S45.

Grundman, M. Vitamin E and Alzheimer disease: the basis for additional clinical trials (1). Am. J. Clin. Nutr. 2000; 71(2, Pt. 2): 630S-636S.

Gustilo, M.C., Markowska, A.L. et al. Evidence that nerve growth factor influences recent memory through structural changes in septohippocampal cholinergic neurons. J. Comp. Neurol. 1999; 405(4): 491-507.

Hamon, C.G., Blair, J.A. et al. The effect of tetrahydrofolate on tetrahydrobiopterin metabolism. J. Mental Deficiency Res. 1986; 30(Pt. 2): 179-83.

Harkness, R., Bratman, S. Drug-Herb-Vitamin Interactions Bible 2000. Roseville, CA: Prima Publishing.

Heiss, W.D., Kessler, J. et al. Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation. Dementia 1994; 5(2): 88-98.

Higgins, J.P., Flicker, L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst. Rev. 2000; 4.

Hillen, T., Lun, A. et al. DHEA-S plasma levels and incidence of Alzheimer's disease. Biol. Psychiatry 2000; 47(2): 161-3.

Hipkiss, A.R. Carnosine, a protective, anti-ageing peptide? Int. J. Biochem. Cell Biol. 1998; 30(8): 863-8.

Hipkiss, A.R., Preston, J.E. et al. Pluripotent protective effects of carnosine, a naturally occurring dipeptide. Ann. N.Y. Acad. Sci. 1998; 854: 37-53.

Horning, M.S., Blakemore, L.J. et al. Endogenous mechanisms of neuroprotection: role of zinc, copper, and carnosine. Brain Res. 2000; 852(1): 56-61.

Horrocks, L.A., Yeo, Y.K. Health benefits of docosahexaenoic acid (DHA). Pharmacol. Res. 1999; 40(3): 211-25.

Huang, W., Alexander, G.E. et al. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study. Am. J. Psychiatry 1999; 156(12): 1879-86.

Hull, M.S., Stauss, S. et al. Inflammatory mechanisms in Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 1996; 246(3): 124-8.

Iwamoto, N.N., Nishiyama, E. Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci. Lett. 1994; 177: 1-2.

Jain, K.K. Evaluation of memantine for neuroprotection in dementia. Expert Opin. Invest. Drugs 200; 9(6): 1397-1406.

Jimenez-Jimenez, F.J., de Bustos, F. et al. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease. J. Neural Transm. 1997; 104(6-7): 703-10.

Jimenez-Jimenez, F.J., Molina, J. A. et al. Serum levels of beta-carotene, alpha-carotene and vitamin A in patients with Alzheimer's disease. Eur. J. Neurol. 1999; 6(4): 495-7.

Joe, B., Lakesh, B.R. Effect of curcumin and capsaicin on arachidonic acid metabolism and lysosomal enzyme secretion by rat peritoneal macrophages. Lipids 1997; 32(11): 1173-80.

Joosten, E., Lesaffre, E. et al. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J. Gerontol. A Biol. Sci. Med. Sci. 1997; 52(2): M76-M79.

Kalmijn, S., Launer, L.J. et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann. Neurol. 1997; 42(5): 776-82.

Kay, A.D., Milstien, S. et al. Cerebrospinal fluid biopterin is decreased in Alzheimer's disease. Arch. Neurol. 1986; 43(10): 996-9.

Khalsa, D.S. Brain Longevity 1997. New York: Warner Books.

Kidd, P.M. A review of nutrients and botanicals in the integrative management of
cognitive dysfunction. Altern. Med. Rev. 1999; 4(3): 144-61.

King, R.G. Do raised brain aluminium levels in Alzheimer's dementia contribute to cholinergic neuronal deficits? Med. Hypotheses 1984; 14(3): 301-6.

Kontush, A., Mann, U. et al. Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease. Free Radic. Biol. Med. 2001; 31(3): 345-54.

Kornhuber, J., Weller, M. et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J. Neural Transm. Suppl. 1994; 43: 91-104.

Kumar, A.M., Tims, F. et al. Music therapy increases serum melatonin levels in patients with Alzheimer's disease. Altern. Ther. Health Med. 1999; 5(6): 49-57.

Kyle, D.J., Schaefer, E. et al. Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids 1999; 34(Suppl.): S245.

Lahiri, D.K. Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. J. Pineal Res. 1999; 26(3): 137-46.

Lahiri, D.K., Ghosh, C. Interactions between melatonin, reactive oxygen species, and nitric oxide. Ann. N.Y. Acad. Sci. 1999; 893: 325-30.

Le Bars, P.L., Katz, M.M. et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997; 278(16): 1327-32.

Le Bars, P.L., Kieser, M. et al. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia. Dement. Geriatr. Cogn. Disord. 2000; 11(4): 230-7.

Leblhuber, F., Walli, J. et al. Hyperhomocysteinemia in dementia. J. Neural Transm. 2000; 107(12): 1469-74.

Lehmann, M., Gottfries, C.G. et al. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement. Geriatr. Cogn. Disord. 1999; 10(1): 12-20.

Lim, G.P., Yang, F. et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 2000; 20(15): 5709-14.

Little, A., Levy, R. et al. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1985; 48(8): 736-42.

Liu, R.Y., Zhou, J.N. et al. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon 4/4 genotype. J. Clin. Endocrinol. Metab. 1999; 84(1): 323-7.

Lopez-Arrieta, J.M., Rodriguez, J.L. et al. Efficacy and safety of nicotine on Alzheimer's disease patients. Cochrane Database Syst. Rev. 2001; 2.

Mackenzie, I.R., Munoz, D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 1998; 50(4): 986-90.

Magri, F., Terenzi, F. et al. Association between changes in adrenal secretion and cerebral morphometric correlates in normal aging and senile dementia. Dement. Geriatr. Cogn. Disord. 2000; 11(2): 90-9.

Martin, J.B. Molecular basis of the neurodegenerative disorders. N. Engl. J. Med. 1999; 340(25): 1970-80.

Maurizi, C.P. The therapeutic potential for tryptophan and melatonin: possible roles in depression, sleep, Alzheimer's disease and abnormal aging. Med. Hypotheses 1990; 31(3): 233-42.

McCaddon, A., Davies, G. et al. Total serum homocysteine in senile dementia of Alzheimer type. Int. J. Geriatr. Psychiatry 1998; 13(4): 235-9.

McCaddon, A., Hudson, P. et al. Analogues, ageing and aberrant assimilation of vitamin B12 in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2001a; 12(2): 133-7.

McCaddon, A., Hudson, P. et al. Homocysteine and cognitive decline in healthy elderly. Dement. Geriatr. Cogn. Disord. 2001b; 12(5): 309-13.

McCarty, M.F. Vascular nitric oxide, sex hormone replacement, and fish oil may help to prevent Alzheimer's disease by suppressing synthesis of acute-phase cytokines. Med. Hypotheses 1999; 53(5): 369-74.

McDermott, J.R., Smith, A.I. et al. Brain aluminum in aging and Alzheimer disease. Neurology 1979; 29(6): 809-14.

McGeer, E.G., McGeer, P.L. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr. Pharmaceut. Design 1999; 5(10): 821-36.

McLachlan, D.R., Bergeron, C. et al. Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. Neurology 1996; 46(2): 401-5.

Meins, W., Muller-Thomsen, T. et al. Subnormal serum vitamin B12 and behavioural and psychological symptoms in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2000; 15(5): 415-8.

Miller, J.W. Homocysteine and Alzheimer's disease. Nutr. Rev. 1999; 57(4): 126-9.

Morris, M.C., Beckett, L.A. et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1998; 12(3): 121-6.

Morrison, L.D., Smith, D.D. et al. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J. Neurochem. 1996; 67(3): 1328-31.

Muller, W.E., Eckert, G.P. et al. Piracetam: novelty in a unique mode of action. Pharmacopsychiatry 1999; 1: 2-9.

Munch, G., Mayer, S. et al. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim. Biophys. Acta 1997; 1360(1): 17-29.

Murialdo, G., Nobili, F. et al. Hippocampal perfusion and pituitary-adrenal axis in Alzheimer's disease. Neuropsychobiology 2000; 42(2): 51-7.

Nagasawa, H., Kogure, K. et al. Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography. Tohoku J. Exp. Med. 1990; 162(3): 225-33.

Neely, M.D., Zimmerman, L. et al. Congeners of N (alpha)-acetyl-L-cysteine but not aminoguanidine act as neuroprotectants from the lipid peroxidation product 4-hydroxy-2-nonenal. Free Radic. Biol. Med. 2000 Nov 15; 29(10): 1028-36.

Newman, P.E. Alzheimer's disease revisited. Med. Hypotheses 2000; 54(5): 774-6.

Newman, P.E. Could diet be one of the causal factors of Alzheimer's disease? Med. Hypotheses 1992; 39(2): 123-6.

Nishizaki, T., Matsuoka, T. et al. Presynaptic nicotinic acetylcholine receptors as a functional target of nefiracetam in inducing a long-lasting facilitation of hippocampal neurotransmission. Alzheimer Dis. Assoc. Disord. 2000; 14(Suppl. 1): S82-S94.

Nitta, A., Hasegawa, T. et al. Oral administration of idebenone, a stimulator of NGF synthesis, recovers reduced NGF content in aged rat brain. Neurosci. Lett. 1993; 163(2): 219-22.

Nitta, A., Murakami, Y. et al. Oral administration of idebenone induces nerve growth factor in the brain and improves learning and memory in basal forebrain-lesioned rats. Naunyn Schmiedebergs Arch. Pharmacol. 1994; 349(4): 401-7.

Olin, J., Schneider, L. et al. Hydergine for dementia. Cochrane Database Syst. Rev. 2000; 2.

Otsuka, M. Analysis of dietary factors in Alzheimer's disease: clinical use of nutritional intervention for prevention and treatment of dementia. Nippon Ronen Igakkai Zasshi 2000; 37(12): 970-3 (in Japanese).

Paganini-Hill, A., Henderson, V.W. Estrogen deficiency and risk of Alzheimer's disease in women. Am. J. Epidemiol. 1994; 140(3): 256-61.

Paganini-Hill, A., Henderson, V.W. Estrogen replacement therapy and risk of Alzheimer disease. Arch. Intern. Med. 1996; 156(19): 2213-7.

Pappolla, M.A., Chyan, Y.J. et al. Alzheimer beta protein mediated oxidative damage of mitochondrial DNA: prevention by melatonin. J. Pineal Res. 1999; 27(4): 226-9.

Park, H., Jang, J. et al. A concise synthetic pathway for trans-metanicotine analogues. Arch. Pharm. Res. 2000; 23(3): 202-5.

Perlmutter, D. BrainRecovery.com 2000. Naples, FL: The Perlmutter Health Center.

Perry, E.K., Pickering, A.T. et al. Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J. Pharm. Pharmacol. 1999; 51(5): 527-34.

Peters, B.H., Levin, H.S. Effects of physostigmine and lecithin on memory in Alzheimer disease. Ann. Neurol. 1979; 6(3): 219-21.

Pettegrew, J.W., Levine, J. et al. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol. Psychiatry 2000; 5(6): 616-32.

Pizzorno, J.E., Murray, M.T. Alzheimer's Disease. A Textbook of Natural Medicine 1995. Seattle, WA: Bastyr College Publications.

Pocernich, C.B., La Fontaine, M. et al. In vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain. Neurochem. Int. 2000; 36(3): 185-91.

Porter, R.J., Lunn, B.S. et al. Cognitive deficit induced by acute tryptophan depletion in patients with Alzheimer's disease. Am. J. Psychiatry 2000; 157(4): 638-40.

Preston, J.E., Hipkiss, A.R. et al. Toxic effects of beta-amyloid (25-35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and beta-alanine. Neurosci. Lett. 1998; 242(2): 105-8.

Ramamurthy, B., Hook, P. et al. An overview of carbohydrate-protein interactions with specific reference to myosin and ageing. Acta Physiol. Scand. 1999; 167(4): 327-9.

Regland, B., Blennow, K. et al. The role of the polymorphic genes apolipoprotein E and methylene-tetrahydrofolate reductase in the development of dementia of the Alzheimer type. Dement. Geriatr. Cogn. Disord. 1999; 10(4): 245-51.

Reiter, R.J., Cabrera, J. et al. Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism. Ann. N.Y. Acad. Sci. 1999; 890: 471-85.

Renvall, M.J., Spindler, A.A. et al. Nutritional status of free-living Alzheimer's patients. Am. J. Med. Sci. 1989; 298(1): 20-7.

Riviere, S., Birlouez-Aragon, I. et al. Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int. J. Geriatr. Psychiatry 1998; 13(11): 749-54.

Robert, P.H., Gokalsing, E. et al. Cholinergic hypothesis and Alzheimer's disease: the place of donepezil (Aricept). Encephale 1999; 5: 23-7.

Sano, M., Ernesto, C. et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 1997; 336(17): 1216-22.

Sawada, M., Hirata, Y. et al. Tyrosine hydroxylase, tryptophan hydroxylase, biopterin, and neopterin in the brains of normal controls and patients with senile dementia of Alzheimer type. J. Neurochem. 1987; 48(3): 760-4.

Scali, C., Prosperi, C. et al. Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease. Eur. J. Neurosci. 2000; 12(6): 1900-12.

Schofield, P.W., Tang, M. et al. Alzheimer's disease after remote head injury: an incidence study. J. Neurol. Neurosurg. Psychiatry 1997; 62(2): 119-24.

Schroeter, H., Williams, R.J. et al. Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low-density lipoprotein. Free Radic. Biol. Med. 2000; 29(12): 1222-33.

Serot, J.M., Christmann, D. et al. CSF-folate levels are decreased in late-onset AD patients. J. Neural Transm. 2001; 108(1): 93-9.

Shankaranarayana Rao, B.S., Lakshmana, M.K. et al. Chronic (-) deprenyl administration alters dendritic morphology of layer III pyramidal neurons in the prefrontal cortex of adult Bonnett monkeys. Brain Res. 1999; 821(1): 218-23.

Stern, Y., Gurland, B. et al. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994; 271(13): 1004-10.

Stewart, W.F., Kawas, C. et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48(3): 626-32.

Suuronen, T., Kolehmainen, P. et al. Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. Biochem. Pharmacol. 2000; 59(12): 1589-95.

Tabet, N., Birks, J. et al. Vitamin E for Alzheimer's disease. Cochrane Database Syst. Rev. 2000; 4.

Tang, X.C. Huperzine A (shuangyiping): a promising drug for Alzheimer's disease. Zhongguo Yao Li Xue Bao 1996; 17(6): 481-4.

Tariska, P., Paksy, A. Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia. Orv. Hetil. 2000; 141(22): 1189-93.

Thal, L.J., Calvani, M. et al. A 1-year controlled trial of acetyl-L-carnitine in early onset AD. Neurology 2000; 55(6): 805-10.

Thal, L.J., Fuld, P.A. et al. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann. Neurol. 1983; 13(5): 491-6.

Thomas, T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol. Aging 2000; 21(2): 343-8.

Thome, J., Kornhuber, J. et al. New hypothesis on etiopathogenesis of Alzheimer syndrome. Advanced glycation end products (AGEs). Nervenarzt 1996; 67(11): 924-9.

Trombley, P.Q., Horning, M.S. et al. Interactions between carnosine and zinc and copper: implications for neuromodulation and neuroprotection. Biochemistry 2000; 65(7): 807-16.

van Dongen, M.C., van Rossum, E. et al. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J. Am. Geriatr. Soc. 2000; 48(10): 1183-94.

Veinbergs, I., Mallory, M. et al. Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice. Eur. J. Neurosci. 2000; 12(12): 4541-6.

Virmani, M.A., Caso, V. et al. The action of acetyl-L-carnitine on the neurotoxicity evoked by amyloid fragments and peroxide on primary rat cortical neurones. Ann. N.Y. Acad. Sci. 2001; 939: 162-78.

Wang, H.X., Wahlin, A. et al. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology 2001; 56(9): 1188-94.

Wang, L.M., Han, Y.F. et al. Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Eur. J. Pharmacol. 2000; 398(1): 65-72.

Wettstein, A. Cholinesterase inhibitors and gingko extracts-are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. Phytomedicine 2000; 6(6): 393-401.

Weyer, G., Babej-Dolle, R.M. et al. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 1997; 36(2): 73-82.

Widner, B., Leblhuber, F. et al. Tryptophan degradation and immune activation in Alzheimer's disease. J. Neural Transm. 2000; 107(3): 343-53.

Winblad, B., Poritis, N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatry 1999; 14(2): 135-46.

Wisniewski, H.M., Wen, G.Y. Aluminium and Alzheimer's disease. Ciba Found. Symp. 1992; 169: 142-54.

Xu, S.S., Guo, Z.X. et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li Xue Bao 1995; 16(5): 391-5.

Yaffe, K., Sawaya, G. et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998; 279(9): 688-95.

Yamada, K., Nitta, A. et al. Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Behav. Brain Res. 1997; 83(1-2): 117-22.

Yamada, K., Tanaka, T. et al. Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. Eur. J. Neurosci. 1999; 11(1): 83-90.

Yao, Z., Drieu, K. et al. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res. 2001; 889(1-2): 181-90.

Yao, Z.X., Drieu, K. et al. Free radicals and lipid peroxidation do not mediate beta-amyloid-induced neuronal cell death. Brain Res. 1999; 847(2): 203-10.

Yatin, S.M., Yatin, M. et al. Alzheimer's amyloid beta-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: protective effect of vitamin E. Neurosci. Lett. 1999; 263(1): 17-20.

Yehuda, S., Rabinovtz, S. et al. Essential fatty acids preparation (SR-3) improves Alzheimer's patients' quality of life. Int. J. Neurosci. 1996; 87(3-4): 141-9.

Youdim, K.A., Martin A. et al. Essential fatty acids and the brain: possible health implications. Int. J. Dev. Neurosci. 2000; 18(4-5): 383-99.

Zhou, L.J., Zhu, X.Z. Reactive oxygen species-induced apoptosis in PC12 cells and protective effect of bilobalide. J. Pharmacol. Exp. Ther. 2000; 293(3): 982-8.

Risk Factors

Ashford, J.W., Mortimer, J.A. Non-familial Alzheimer's disease is mainly due to genetic factors. J. Alzheimers Dis. 2002 Jun; 4(3): 169-77.

Bowirrat, A., Friedland, R.P., Farrer, L., Baldwin, C., Korczyn, A. Genetic and environmental risk factors for Alzheimer's disease in Israeli Arabs. J. Mol. Neurosci. 2002 Aug-Oct; 19(1-2): 239-45.

Crawford, J.G. Alzheimer's disease risk factors as related to cerebral blood flow. Med. Hypotheses 1996 Apr; 46(4): 367-77.

Crawford, J.G. Alzheimer's disease risk factors as related to cerebral blood flow: additional evidence. Med. Hypotheses 1998 Jan; 50(1): 25-36.

de la Torre, J.C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002 Apr; 33(4): 1152-62.

de la Torre, J.C. Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging. Gerontology 1997; 43(1-2): 26-43.

de la Torre, J.C. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann. N.Y. Acad. Sci. 2000; 924: 136-52.

Eikelenboom, P., Hoogendijk, W.J., Jonker, C., van Tilburg, W. Immunological mechanisms and the spectrum of psychiatric syndromes in Alzheimer's disease. J. Psychiatr. Res. 2002 Sep-Oct; 36(5): 269-80.

Heinonen, O., Syrjanen, S., Mantyjarvi, R., Syrjanen, K., Riekkinen, P. JC virus infection and Alzheimer's disease: reappraisal of an in situ hybridization approach. Ann. Neurol. 1992 Apr; 31(4): 439-41.

Itzhaki, R.F., Lin, W.R., Shang, D. et al. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet 1997 Jan 25; 349(9047): 241-4.

Jorm, A.F. Alzheimer's disease: risk and protection. Med. J. Aust. 1997 Oct 20; 167(8): 443-6.

Kidd, P.M. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern. Med. Rev. 1999 Jun; 4(3): 144-61.

Kim, S.H., Cairns, N., Fountoulakisc, M., Lubec, G. Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease. Neurosci. Lett. 2001 Mar 2; 300(1): 41-4.

Lindsay, J., Laurin, D., Verreault, R., Hebert, R. et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol. 2002 Sep 1; 156(5): 445-53.

Minger, S.L., Esiri, M.M., McDonald, B. et al. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 2000 Nov 28; 55(10): 1460-7.

Perry, E., Walker, M., Grace, J., Perry, R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999 Jun; 22(6): 273-80.

Ravaglia, G., Forti, P., Maioli, F., Sacchetti, L. et al. Education, occupation, and prevalence of dementia: findings from the Conselice Study. Dement. Geriatr. Cogn. Disord. 2002; 14(2): 90-100.

Schofield, P.W., Tang, M., Marder, K. et al. Alzheimer's disease after remote head injury: an incidence study. J. Neurol. Neurosurg. Psychiatry 1997 Feb; 62(2): 119-24.

Small, G.W. The pathogenesis of Alzheimer's disease. J. Clin. Psychiatry 1998; 59(Suppl. 9): 7-14.

Sparks, D.L., Connor, D.J., Browne, P., Sabbagh, M.N. Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated? J. Mol. Neurosci. 2002 Aug-Oct; 19(12): 209-12.

Warkentin, S., Passant, U. Functional imaging of the frontal lobes in organic dementia. Regional cerebral blood flow findings in normals, in patients with frontotemporal dementia and in patients with Alzheimer's disease performing a word fluency test. Dement. Geriatr. Cogn. Disord. 1997 Mar-Apr; 8(2): 105-9.